The agency alleges CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx accepted money from drugmakers in ...
The Federal Trade Commission alleges that pharmacy benefits managers prioritized high rebates from drug makers for insulin over lower prices for consumers, leading to inflated out-of-pocket costs.
FTC sues top PBMs for inflating insulin prices, accusing them of rigging competition and hurting patients. Legal action also includes GPOs.
The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged ...
PBMs, like Optum Rx, are the key counterweight to pharmaceutical companies’ otherwise unchecked monopoly power to set and raise drug prices.
Cigna may have the edge with smaller footprint and focused approach, but all three giants face risks from FTC's lawsuit over inflated insulin prices.
The Federal Trade Commission on Friday sued prescription-drug middlemen owned by CVS Health Corp., Cigna Group and UnitedHealth Group Inc., alleging that they artificially pumped up prices of insulin ...
The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the ...
The Federal Trade Commission brought action against the three largest prescription drug benefit managers (PBMs)—Caremark Rx ...
In a statement, the FTC wrote that an executive at a PBM acknowledged this strategy for insulins, saying that the big three PBMs continue to “drink down the tasty … rebates.” PBMs pushed back Friday ...
The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback